Amikacin

Suppresses premature stop mutation

Phase of research

FDA-approved for Cystic Fibrosis

How it helps

Anti-Infective,Restore CFTR Function

General information

Amikacin is a small-molecule aminoglycoside antibiotic effective against resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumanii. It was approved in the USA in 2018 and is sold under the brand name Arikayce®. It is used to treat Mycobacterium avium complex lung disease. In relation to cystic fibrosis, our AIM tool found the data that amikacin reduces Pseudomonas aeruginosa density, which leads to improved lung function. Amikacin can also suppress premature stop mutation (nonsense mutation) in the CFTR gene.

Amikacin on PubChem
Amikacin on DrugBank
Amikacin on Wikipedia

Synonyms

amikacin sulfate

Marketed as

Arikayce - prescribing information

Dietary sources

N/A

C₂₂H₄₃N₅O₁₃

Drug-Mutation Relation

results for W1089X / D110H

See all data on Amikacin

Treats

Mutation	Link	Tested on	Impact factor	Notes
General effect	Amikacin for Inhalation (Transave) (Insmed TR02-106)	humans	N/A
General effect	Arikace compared to TOBI® in people with CF with chronic Pseudomonas aeruginosa infections (Insmed TR02-108)	humans	N/A	Less effective than tobramycin.
General effect	Amikacin for Inhalation (Transave) (Insmed TR02-106)	humans	N/A

Does not treat

Mutation	Link	Tested on	Impact factor	Notes